Anifrolumab Phase III trial meets primary endpoint in systemic lupus erythematosus

Click here to view online. Add this email to your safelist.

29 August 2019

AstraZeneca today announced that the Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of systemic lupus erythematosus (SLE), met its primary endpoint, achieving a statistically-significant and clinically-meaningful reduction in disease activity versus placebo, with both arms receiving standard of care.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.